Clinical Trial Update: Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fibrinolytic therapy for acute respiratory distress syndrome associated with COVID-19 has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Respiratory Failure
• Respiratory Syndrome

Snippet

Sponsor: Denver Health and Hospital Authority | Conditions: Severe Acute Respiratory Syndrome, Respiratory Failure | Phase 2 | Status: COMPLETED | Results posted: 2022-01-20